BRAF and non-small cell lung carcinoma: The increased expression of EGFR or mutations in the intracellular domain of the EGFR have been reported in 43–89% of NSCLC;44,45 BRAF mutations were observed in 2–4% of lung ADCs;46 and KRAS mutations were detected in 20–30% of NSCLC47.